Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.60 |
| ▸ | WNT3A | P56704 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418918 | 0.85 | MAOB (0.58) | CTNNB1WNT3AROCK2ROCK1MAOB | |
| SCHEMBL5419581 | 0.84 | ROCK2 (0.62) | CTNNB1WNT3AROCK2ROCK1EPHX2 | |
| SCHEMBL5409039 | 0.83 | MAPT (0.60) | CTNNB1WNT3AROCK2ROCK1PPARG | |
| SCHEMBL3470577 | 0.82 | EPHX2 (0.67) | CTNNB1WNT3AROCK2ROCK1EPHX2 | |
| SCHEMBL3640238 | 0.81 | ROCK2 (0.59) | CTNNB1WNT3AROCK2ROCK1PTGES | |
| SCHEMBL5413661 | 0.81 | MAOB (0.56) | CTNNB1WNT3AROCK2ROCK1MAOB | |
| SCHEMBL5412630 | 0.80 | ROCK2 (0.64) | ROCK2ROCK1MAOB | |
| SCHEMBL5179231 | 0.80 | MAOB (0.70) | CTNNB1WNT3AROCK2ROCK1MAOB | |
| SCHEMBL5412689 | 0.80 | MAOB (0.67) | CTNNB1WNT3AROCK2ROCK1EPHX2 | |
| SCHEMBL5409267 | 0.79 | DDR2 (0.69) | ROCK2ROCK1MAOBMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | CTNNB1 2647/4885WNT3A 3494/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.